Oura Inc. set the terms for its landmark initial public offering on September 21, 2026, launching an institutional roadshow to offer 50,000,000 shares of common stock at an estimated price range of $40.00 to $44.00 per share. According to the company’s Amendment No. 1 to Form S-1 filed with the U.S. Securities and Exchange Commission (SEC), the offering will raise up to $2.20 billion in aggregate gross proceeds, conferring a basic market capitalization of up to $14.12 billion and a fully diluted valuation of approximately $15.62 billion at the upper end of the range.
The filing follows our previous coverage of Oura’s initial S-1 filing on September 9, which revealed the smart-ring pioneer had crossed $1.21 billion in nine-month revenue with GAAP profitability. The new pricing terms establish Oura as the premier consumer hardware-subscription offering of 2026, featuring substantial cornerstone support and a controlled primary capital expansion.
Key Takeaways
- Offering Scale and Valuation: Oura is marketing 50 million shares between $40.00 and $44.00 per share to list on the Nasdaq Global Select Market under the ticker “OURA.” At the $44.00 ceiling, basic equity is valued at $14.12 billion across 320,945,459 post-offering basic shares.
- Primary vs. Secondary Split: Oura is offering 13,500,000 primary shares to raise approximately $532.6 million in estimated net proceeds at the $42.00 midpoint, while existing stockholders are selling 36,500,000 shares.
- Cornerstone Anchors: Healthcare giant Eli Lilly and Company indicated an interest in purchasing up to $100.0 million of stock, while Dragoneer Investment Group indicated an interest in purchasing up to $300.0 million, representing up to $400.0 million in combined cornerstone interest.
- Balance Sheet Liquidity: Pro forma as adjusted cash and cash equivalents will expand from $371.8 million as of June 30, 2026, to approximately $764.2 million following the close of the transaction.
The Offering Structure: Primary Capital and Secondary Liquidity
A central feature of Oura’s IPO terms is the division between primary growth capital and secondary liquidity for early venture backers and employees. Of the 50 million shares on offer, 13.5 million shares are newly issued primary stock by Oura Inc., while 36.5 million shares are secondary offerings sold by existing stockholders. Oura will receive no proceeds from shares sold by existing stockholders.
| Offering Metric | Low End ($40.00) | Midpoint ($42.00) | High End ($44.00) |
|---|---|---|---|
| Primary Shares Offered | 13,500,000 | 13,500,000 | 13,500,000 |
| Secondary Shares Offered | 36,500,000 | 36,500,000 | 36,500,000 |
| Total Base Offering Shares | 50,000,000 | 50,000,000 | 50,000,000 |
| Gross Offering Value | $2.00 billion | $2.10 billion | $2.20 billion |
| Net Proceeds to Company (est.) | $506.7 million | $532.6 million | $558.5 million |
| Post-Offering Basic Shares | 320,945,459 | 320,945,459 | 320,945,459 |
| Basic Market Capitalization | $12.84 billion | $13.48 billion | $14.12 billion |
In addition to the base 50 million share float, the underwriting syndicate led by Goldman Sachs, Morgan Stanley, and J.P. Morgan holds a 30-day option to purchase up to an additional 7,500,000 secondary shares from selling stockholders to manage over-allotments. If exercised in full, the total transaction size would reach 57,500,000 shares, representing $2.53 billion in total capital transferred at the top of the marketed range.
Valuation Sensitivity and Capitalization Bridge
At the midpoint price of $42.00 per share, Oura will command an initial basic equity value of $13.48 billion. Factoring in 21,746,410 options and 10,842,504 restricted stock units (RSUs) outstanding under existing equity incentive plans, the fully diluted share count reaches approximately 355 million shares, translating into an implied fully diluted valuation of $14.91 billion at midpoint and $15.62 billion at $44.00.
Cornerstone Endorsements: Eli Lilly and Dragoneer
To de-risk the public float in a volatile market environment, Oura secured high-profile non-binding indications of interest from two premier institutional partners. Pharmaceutical major Eli Lilly and Company indicated an interest in purchasing up to $100.0 million of common stock at the public offering price, while technology asset manager Dragoneer Investment Group indicated an interest in purchasing up to $300.0 million. Together, these indications represent up to $400.0 million, or approximately 18% of the total base offering.
The strategic commitment from Eli Lilly is particularly notable for capital markets observers. As digital health converges with metabolic and chronic disease management, Oura’s biometric telemetry on sleep, metabolic health, and cardiorespiratory metrics provides valuable digital biomarker synergy. Although indications of interest are non-binding agreements and underwriters may allocate more or fewer shares, cornerstone participation creates a dependable demand floor during the bookbuilding process.
Financial Trajectory and Cash Inflow
Unlike earlier generations of consumer wearables that relied on dilutive debt facilities to subsidize operating losses, Oura enters the public market self-funding. The company generated $1.21 billion in revenue and $60.77 million in net income for the nine months ended June 30, 2026, driven by continuous hardware sales of the Oura Ring 4 and rapid growth in its $5.99-per-month recurring subscription base, which now exceeds 5.0 million active members.
After deducting underwriting discounts and estimated offering expenses of $13.5 million, Oura expects to pocket approximately $532.6 million in net primary proceeds at midpoint. Combined with its existing cash balance of $371.8 million and short-term investments, Oura’s pro forma liquidity will expand to $764.2 million, providing an robust balance sheet to support research and development, enterprise clinical integrations, and supply chain working capital.
What to Watch Next in the Roadshow
Institutional bookbuilding will take place over the coming week, with final pricing expected during the week of September 28, 2026. Market participants should monitor three critical developments as Oura tests institutional appetite:
- Order Book Coverage and Price Discovery: Whether robust demand drives pricing above the $44.00 high end, echoing recent premium tech and software debuts. Readers can navigate foundational offering concepts in our educational market guide.
- Cornerstone Allocation Finalization: The final percentage of shares allocated to Eli Lilly and Dragoneer in the final prospectus filing (Form 424B4).
- First-Day Trading Mechanics: The debut performance under ticker “OURA” on the Nasdaq, which will set the baseline multiple for the broader digital health hardware peer group.
Sources
- SEC EDGAR — Oura Inc. Form S-1/A Registration Statement (September 21, 2026)
- ECMSource — Oura Files for Nasdaq IPO: $1.2B Revenue, $61M Net Income (September 9, 2026)
- Oura Health — Oura Ring 4 Technical Specifications and Subscription Terms
- ECMSource — Market Structure & Offerings Learning Hub
Disclosure: This article is for informational purposes only and is not investment advice.